Full text
Earnings transcript
Read the complete earnings call transcript.
RVTY
Revvity, Inc.
$88.94
1.02
(1.16%)
| Exchange: | NYSE |
| Market Cap: | 9.944B |
| Shares Outstanding: | 107.115M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Prahlad R. Singh | |||||
| Full Time Employees: | 11000 | |||||
| Address: |
| |||||
| Website: | http://www.revvity.com |
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2,750,571 | 2,755,026 | 2,856,051 |
| Gross Profit | 1,322,191 | 1,322,659 | 1,516,065 |
| EBITDA | 713,558 | 840,253 | 662,723 |
| Operating Income | 399,491 | 410,519 | 356,635 |
| Net Income | -118,378 | 295,833 | 241,675 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 13,564,665 | 12,392,478 | 12,168,411 |
| Total Liabilities | 5,691,926 | 4,725,604 | 4,918,051 |
| Total Stockholders Equity | 7,872,739 | 7,666,874 | 7,250,360 |
| Total Debt | 4,065,295 | 3,325,805 | 3,368,172 |
| Cash and Cash Equivalents | 913,163 | 1,163,396 | 919,866 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 91,272 | 628,299 | 588,956 |
| Capital Expenditure | -81,368 | -86,648 | -73,522 |
| Free Cash Flow | 9,904 | 541,651 | 515,434 |
| Net Income | 179,503 | 283,071 | 241,201 |
| Net Change in Cash | 443,627 | 250,079 | -244,586 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 3,656,336.869 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 3,719,811.154 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 3,684,576.800 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,152,528.545 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,172,536.528 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,161,430.166 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 887,516.253 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 907,591.360 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 896,447.706 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 928,669.537 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 944,791.311 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 935,842.171 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 7.920 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 8.020 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 7.840 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 4 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Stable Financial Performance: Revvity reported a 1% organic growth in Q3 2025, as highlighted in the earnings call transcript, indicating resilience in a competitive market. Key financial metrics such as revenue and net income from the income statements show consistent performance over recent periods, supported by positive operating cash flow from cash flow statements.
- Innovation Focus: The company is actively leveraging artificial intelligence (AI) both internally for operational efficiencies and externally for new market solutions, as noted in the Q3 2025 earnings call summary. This positions Revvity as a forward-thinking player in its industry.
- Strong Liquidity Position: Balance sheet data reveals a healthy level of cash and cash equivalents alongside a favorable current ratio (from key metrics TTM), suggesting the company is well-equipped to manage short-term obligations and invest in growth initiatives.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates RVTY intrinsic value between $64.89 – $68.62 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about RVTY valuation
Is Revvity, Inc. (RVTY) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Revvity, Inc. (RVTY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is RVTY a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether RVTY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is RVTY’s P/E ratio?
You can see RVTY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for RVTY?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is RVTY a good long-term investment?
Whether RVTY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
RVTY
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.16
Trading Metrics:
| Open: | 86.28 | Previous Close: | 87.92 | |
| Day Low: | 85.8 | Day High: | 90.63 | |
| Year Low: | 81.36 | Year High: | 118.3 | |
| Price Avg 50: | 96.44 | Price Avg 200: | 95.2 | |
| Volume: | 786400 | Average Volume: | 1.226M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeRVTY full analysis
Welcome to MARKETSNAP’s SWOT analysis for Revvity, a name you might not hear every day but one that’s carving out a solid spot in the life sciences and diagnostics space. I’m pumped to dive into this with you today because Revvity, formerly known as PerkinElmer and trading under the ticker RVTY, is a company with some intriguing dynamics for long-term investors like us. Whether you’re looking to build wealth over decades or just curious about what’s moving this stock right…
